» Articles » PMID: 33048477

Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers

Overview
Journal Clin Transl Sci
Date 2020 Oct 13
PMID 33048477
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Lisinopril, a highly hydrophilic long-acting angiotensin-converting enzyme inhibitor, is frequently prescribed for the treatment of hypertension and congestive heart failure. Green tea consumption may reduce the risk of cardiovascular outcomes and total mortality, whereas green tea or its catechin components has been reported to decrease plasma concentrations of a hydrophilic β blocker, nadolol, in humans. The aim of this study was to evaluate possible effects of green tea extract (GTE) on the lisinopril pharmacokinetics. In an open-label, randomized, single-center, 2-phase crossover study, 10 healthy subjects ingested 200 mL of an aqueous solution of GTE containing ~ 300 mg of (-)-epigallocatechin gallate, a major catechin component in green tea, or water (control) when receiving 10 mg of lisinopril after overnight fasting. The geometric mean ratio (GTE/control) for maximum plasma concentration and the area under the plasma concentration-time curve of lisinopril were 0.289 (90% confidence interval (CI) 0.226-0.352) and 0.337 (90% CI 0.269-0.405), respectively. In contrast, there were no significant differences in time to reach maximum lisinopril concentration (6 hours in both phases) and renal clearance of lisinopril (57.7 mL/minute in control vs. 56.9 mL/minute in GTE). These results suggest that the extent of intestinal absorption of lisinopril was significantly impaired in the presence of GTE, whereas it had no major effect on the absorption rate and renal excretion of lisinopril. Concomitant use of lisinopril and green tea may decrease oral exposure to lisinopril, and therefore result in reduced therapeutic efficacy.

Citing Articles

Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma.

Nair S, Hersh E, Margulies K, Daniell H Hypertens Res. 2025; .

PMID: 39837966 DOI: 10.1038/s41440-025-02109-y.


Dietary Supplements for Weight Loss and Drug Interactions.

Rivas Garcia F, Garcia Sierra J, Valverde-Merino M, Zarzuelo Romero M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770500 PMC: 11678256. DOI: 10.3390/ph17121658.


Cardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs-Comprehensive Review.

Nyulas K, Simon-Szabo Z, Pal S, Fodor M, Denes L, Cseh M Int J Mol Sci. 2024; 25(12).

PMID: 38928095 PMC: 11203894. DOI: 10.3390/ijms25126388.


Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants.

Clarke J, Judson S, Tian D, Kirby T, Tanna R, Matula-Pentek A Clin Transl Sci. 2023; 16(10):1779-1790.

PMID: 37639334 PMC: 10582660. DOI: 10.1111/cts.13578.


Possible Side Effects of Polyphenols and Their Interactions with Medicines.

Duda-Chodak A, Tarko T Molecules. 2023; 28(6).

PMID: 36985507 PMC: 10058246. DOI: 10.3390/molecules28062536.


References
1.
Misaka S, Yatabe J, Muller F, Takano K, Kawabe K, Glaeser H . Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. 2014; 95(4):432-8. DOI: 10.1038/clpt.2013.241. View

2.
Tian L, Liu H, Xie S, Jiang J, Han L, Huang Y . Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011; 33(5):655-63. DOI: 10.1016/j.clinthera.2011.04.018. View

3.
Mizukami Y, Sawai Y, Yamaguchi Y . Simultaneous analysis of catechins, gallic acid, strictinin, and purine alkaloids in green tea by using catechol as an internal standard. J Agric Food Chem. 2007; 55(13):4957-64. DOI: 10.1021/jf070323f. View

4.
Moore V, Irwin W, Timmins P, Lambert P, Chong S, Dando S . A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: affinities of ACE inhibitors. Int J Pharm. 2001; 210(1-2):29-44. DOI: 10.1016/s0378-5173(00)00564-0. View

5.
Thind G . Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc Drugs Ther. 1990; 4(1):199-206. DOI: 10.1007/BF01857634. View